KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Net Cash Flow (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Net Cash Flow for 6 consecutive years, with $44.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow rose 39.77% year-over-year to $44.5 million, compared with a TTM value of -$29.5 million through Dec 2025, down 214.99%, and an annual FY2025 reading of -$29.5 million, down 214.99% over the prior year.
  • Net Cash Flow was $44.5 million for Q4 2025 at AbCellera Biologics, up from -$8.7 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $247.0 million in Q2 2022 and bottomed at -$408.8 million in Q3 2022.
  • Average Net Cash Flow over 5 years is -$21.3 million, with a median of -$7.5 million recorded in 2023.
  • Peak annual rise in Net Cash Flow hit 342.17% in 2021, while the deepest fall reached 1145.28% in 2021.
  • Year by year, Net Cash Flow stood at -$16.0 million in 2021, then skyrocketed by 188.59% to $14.2 million in 2022, then tumbled by 382.92% to -$40.2 million in 2023, then skyrocketed by 179.28% to $31.8 million in 2024, then soared by 39.77% to $44.5 million in 2025.
  • Business Quant data shows Net Cash Flow for ABCL at $44.5 million in Q4 2025, -$8.7 million in Q3 2025, and -$67.6 million in Q2 2025.